Filing Details

Accession Number:
0001415889-24-008771
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-20 18:00:25
Reporting Period:
2024-03-18
Accepted Time:
2024-03-20 18:00:25
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1798749 Aerovate Therapeutics Inc. AVTE Pharmaceutical Preparations (2834) 831377888
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1868997 Hunter Gillies C/O Aerovate Therapeutics, Inc.
930 Winter Street, Suite M-500
Waltham MA 02451
Chief Medical Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-03-18 4,000 $1.74 7,251 No 4 M Direct
Common Stock Acquisiton 2024-03-18 3,000 $2.14 10,251 No 4 M Direct
Common Stock Disposition 2024-03-18 6,387 $25.81 3,864 No 4 S Direct
Common Stock Disposition 2024-03-18 613 $26.40 3,251 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2024-03-18 4,000 $0.00 4,000 $1.74
Common Stock Stock Option (Right to Buy) Disposition 2024-03-18 3,000 $0.00 3,000 $2.14
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
4,036 2030-09-03 No 4 M Direct
98,510 2031-04-01 No 4 M Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.25 to $26.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  4. A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
  5. A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.